Key Takeaways Moderna shares surged Tuesday after Canadian regulators approved the biotech firm's updated COVID-19 vaccine. Moderna's Spikevax KP.2 targets the KP.2 variant of the virus. The U.S. Food and Drug Administration has also approved the shot, as well as updated vaccines from Pfizer and BioNTech. Moderna (MRNA) shares surged Tuesday after Canadian regulators approved the biotech firm's updated COVID-19 vaccine. The company reported Health Canada authorized the use of its Spikevax KP.2 shot for thos ...